adenovirus types 4 and 7 live, oral (Rx)

Brand and Other Names:Ardovax
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

tablets, enteric-coated

  • Adenovirus type 4≥4.5 log10 TCID50
  • Adenovirus tyep 7≥4.5 log10 TCID50
more...

Adenovirus Active Immunization

Indicated for active immunization of military populations for prevention of febrile acute respiratory disease caused by adenovirus types 4 and 7

Aged 17-50 years: Single vaccine dose consists of 2 tablets: 1 tablet of adenovirus type 4 and one tablet of adenovirus type 7

Swallow tablets whole, do not chew, crush, or split; chewing a tablet could expose the upper respiratory tract to live adenovirus leading to disease

Storage

  • Refrigerate between 2-8 degrees C (35-46 degrees F); protect from moisture; do not remove desiccant from bottle

<17 years: Safety and efficacy not established

Next:

Interactions

Interaction Checker

and adenovirus types 4 and 7 live, oral

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 
            Previous
            Next:

            Adverse Effects

            Adverse effects were similar to placebo for the first 7 days following vaccination; those listed below were slightly higher than those for placebo

            >10%

            Nasal congestion (15.3%)

            Diarrhea (10.2%)

            Headache (7-30%)

            Nausea (5-14%)

            Cough (10-12%)

            1-10%

            Pyrexia (1.4%)

            Fever (≤1%)

            Limb pain (4%)

            Rhinorrhea (4%)

            <1%

            Gastritis

            Hematuria

            Gastroenteritis

            Pneumonia

            Hematochezia

            Previous
            Next:

            Warnings

            Contraindications

            Hypersensitivity

            Pregnancy

            Inability to swallow table whole (chewing a tablet could expose the upper respiratory tract to live adenovirus leading to disease)

            Cautions

            Vomiting or diarrhea could decrease effectiveness of vaccine

            Safety has not been evaluated in individuals with altered immunocompetence

            Contains live viruses that are shed in the stool and can cause disease if transmitted; those vaccinated should avoid close contact with children younger than 7 years and immunocompromised individuals

            Tablets contain human albumin (<0.3 mg/tablet), which could theortetically increase risk transmission of blood borne diseases (e.g., Creuzfeldt-Jakob disease)

            Effective immunity may not occur in all vaccinated patients

            Previous
            Next:

            Pregnancy & Lactation

            Pregnancy Category: X

            Unknown whether adenovirus can cause fetal harm; naturally occurring infection with adenoviruses has been associated with fetal harm

            Lactation: Unknown whether distributed in breast milk; caution advised

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next:

            Pharmacology

            Mechanism of Action

            Live oral vaccine that replicates in intestinal tract and induces immunity in persons with low or no pre-existing neutralizing antibodies to adenoviruses types 4 and 7

            Pharmacokinetics

            Duration: Viral shedding not detected after 28 days

            Onset: Viral shedding in the stool starts at 7 days; seroconversion starts at 26 days following vaccination

            Absorption: Not detected in serum (limited data)

            Previous
            Next:

            Images

            Previous
            Next:

            Formulary

            FormularyPatient Discounts

            Adding plans allows you to compare formulary status to other drugs in the same class.

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous